Nuveen’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-2,701,137
| Closed | -$10.6M | – | 3617 |
|
|
2022
Q1 | $10.6M | Buy |
2,701,137
+14,584
| +0.5% | +$52.9K | ﹤0.01% | 1599 |
|
|
2021
Q4 | $9.59M | Sell |
2,686,553
-66,987
| -2% | -$234K | ﹤0.01% | 1721 |
|
|
2021
Q3 | $10M | Buy |
2,753,540
+216,874
| +9% | +$877K | ﹤0.01% | 1782 |
|
|
2021
Q2 | $11.1M | Buy |
2,536,666
+148,682
| +6% | +$606K | ﹤0.01% | 1808 |
|
|
2021
Q1 | $9.81M | Buy |
2,387,984
+1,174,117
| +97% | +$5.09M | ﹤0.01% | 1813 |
|
|
2020
Q4 | $4.84M | Buy |
1,213,867
+78,767
| +7% | +$255K | ﹤0.01% | 2095 |
|
|
2020
Q3 | $3.06M | Sell |
1,135,100
-17,965
| -2% | -$49.7K | ﹤0.01% | 2174 |
|
|
2020
Q2 | $3.17M | Buy |
1,153,065
+21,616
| +2% | +$60.3K | ﹤0.01% | 2129 |
|
|
2020
Q1 | $2.67M | Buy |
1,131,449
+18,181
| +2% | +$61.8K | ﹤0.01% | 2045 |
|
|
2019
Q4 | $5.23M | Buy |
1,113,268
+367,856
| +49% | +$1.51M | ﹤0.01% | 1973 |
|
|
2019
Q3 | $2.49M | Buy |
745,412
+60,975
| +9% | +$201K | ﹤0.01% | 2305 |
|
|
2019
Q2 | $2.25M | Buy |
+684,437
| New | +$1.98M | ﹤0.01% | 2379 |
|
|
2016
Q2 | – | Sell |
-10,488
| Closed | -$9K | – | 1437 |
|
|
2016
Q1 | $9K | Buy |
+10,488
| New | +$10.1K | ﹤0.01% | 1389 |
|
Other funds holding ATRS
Nuveen's ATRS Position: Q2 2022 in Review
Nuveen sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 2,701,137 shares — an estimated $10.6M sold.
Nuveen first reported a position in ATRS in Q1 2016 and held it in 13 quarters. The position peaked at $11.1M in Q2 2021. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- Nuveen reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- Nuveen sold 2,701,137 Antares Pharma, Inc. shares in Q2 2022, an estimated $10.6M.
- Nuveen first reported a position in Antares Pharma, Inc. in Q1 2016 and held it in 13 quarters.
- Nuveen's Antares Pharma, Inc. position peaked at $11.1M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.